Stockreport

Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds

ASAHI KAISEI CRP UNSP/ADR  (AHKSY) 
NASDAQ:AMEX Investor Relations: asahi-kasei.co.jp/asahi/en/ir
PDF TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma announced that it has strengthened its drug discovery pipeline through an exclusive global license agreement regarding nov [Read more]